It increases the lifetime risk of certain types of cancer development, especially breast and ovarian cancers, but paradoxically the HRD in the tumor cells makes the cancer susceptible to therapy by poly (ADP-ribose) polymerase (PARP) inhibitors and platinum compounds. The gene discussed is PARP1; the disease is cancer.